Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
- Status
- WITHDRAWN
- Phase
- PHASE3
Clinical Trials Related to Bevacizumab
Related studies linked through entity extraction aliases.
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
- Status
- COMPLETED
- Phase
- PHASE1
To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE3
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
- Status
- COMPLETED
- Phase
- PHASE3
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Status
- RECRUITING
- Phase
- PHASE1
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases
- Status
- UNKNOWN
- Phase
- PHASE2
Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma
- Status
- WITHDRAWN
- Phase
- PHASE3
Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab
- Status
- COMPLETED
- Phase
- PHASE2
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE3